Cyclophosphamide Hepatotoxicity in a Patient with Systemic Lupus Erythematosus
Authors: ANNE M. BACON
Journal: Annals of Internal Medicine (1982)

Brief Reports1 July 1982Cyclophosphamide Hepatotoxicity in a Patient with Systemic Lupus ErythematosusANNE M. BACON, M.D., STUART A. ROSENBERG, M.D.ANNE M. BACON, M.D., STUART A. ROSENBERG, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-1-62 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCYCLOPHOSPHAMIDE (Cytoxan; Mead Johnson and Company, Evansville, Indiana) is a potent cyototoxic agent that is widely used to treat a number of autoimmune disorders in patients unresponsive to conventional therapy. Although patients with connective tissue diseases are known to develop a hepatotoxic reaction to salicylates (1, 2), cyclophosphamide has not previously been proven to cause liver damage in these patients. We report a case of a patient with systemic lupus erythematosus who developed hepatitis after treatment with cyclophosphamide, both on initial therapy and again on rechallenge with the drug. A 23-year-old black woman was found to have systemic lupus erythematosus...References1. SEAMANISHAKPLOTZ WKP. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med. 1974;80:1-8. LinkGoogle Scholar2. RICHJOHNSON RJ. Salicylate hepatotoxicity in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1973;16:1-9. CrossrefMedlineGoogle Scholar3. AUBREY D. Massive hepatic necrosis after cyclophosphamide [Letter]. Br Med J. 1970;3:588. CrossrefMedlineGoogle Scholar4. WALTERSROBINSONDICK-SMITHCORRIGANWEBB DRJAJ. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide. Med J Aust. 1972;2:1070. CrossrefMedlineGoogle Scholar5. PODURGIELMCGILLLUDWIGTAYLORMULLER BDJWS. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc. 1973;48:787-92. MedlineGoogle Scholar6. FAUCIKATZHAYNESWOLFF APBS. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301:235-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Virginia Medical School Charlottesville, Virginia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLupus hepatitis, more than just elevated liver enzymesIntroduction of CyclophosphamideRatlarda Siklofosfamid ile İndüklenen Hepatotoksisite Üzerine Kuersetinin EtkileriCyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based reviewCyclophosphamide İle İndüklenmiş Ratlarda Karaciğer Enzimleri (AST, ALT, ALP) ve Histopatolojisi Üzerine Naringin'in Protektif EtkileriDrugs and ToxinsComputed Tomography Liver Spleen Ratio as Predictive Marker of Liver Injury among Adult Filipina Early Breast Cancer Receiving Neoadjuvant Therapy from 2010-2016: A Six-Year Retrospective StudyThe protective effects of Cichorium glandulosum seed and cynarin against cyclophosphamide and its metabolite acrolein-induced hepatotoxicity in vivo and in vitroChallenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesisChemotherapy-Induced HepatotoxicityAmelioration of cyclophosphamide-induced hepatotoxicity by the root extract of Decalepis hamiltonii in miceHepatotoxicity of Immunosuppressive DrugsDefinition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: Results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifenHepatic injury due to drugs, herbal compounds, chemicals and toxinsDrug-Induced Liver InjuryDrug Monitoring in Systemic Lupus Erythematosus: A Systematic ReviewComparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experienceCancer Chemotherapy II: Atypical Hepatic InjuriesHepatotoxicity of ChemotherapyDrug-Induced Liver InjuryAcute Icteric Hepatitis Induced By a Short Course of Low-Dose Cyclophosphamide in a Patient with Lupus NephritisHepatotoxicity of chemotherapyHepatotoxicity of ChemotherapyCumulative hepatotoxicity induced by continuous low- dose cyclophosphamide therapyCANCER CHEMOTHERAPY AND THE LIVERHEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTSReversible hepatic dysfunction in association with cyclophosphamide therapyCyclophosphamide-Induced Hepatotoxicity in a Patient With Wegener's GranulomatosisDrug-induced cutaneous porphyriaCyclophosphamide related hepatotoxicityLong-Term Complications of Antineoplastic AgentsSystemic Lupus ErythematosusPrediction of organ system toxicity with antirheumatic drug therapyIntravenous Cyclophosphamide Therapy of Severe SLEIntermittent intravenous cyclophosphamide therapy for lupus nephritisDevelopment of porphyria cutanea tarda after treatment with cyclophosphamideMechanisms of Action and Clinical Applications of Cytotoxic Drugs in Rheumatic DisordersMarrow transplantation in hepatitis-associated aplastic anemiaSystemic Lupus ErythematosusCyclophosphamide (Cytoxan)Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases 1 July 1982Volume 97, Issue 1Page: 62-63KeywordsArthritisConnective tissue diseasesCyclophosphamideDrug therapyFellowshipsHepatitis AHospital medicineLiverLupus erythematosusSalicylates Issue Published: 1 July 1982 PDF DownloadLoading ...